Laurent Pharmaceuticals Joins Battle Against COVID-19

MONTREAL, QC, Canada – April 9th, 2020

Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company that spun off from McGill University in 2012, today announces that it is planning to test its lead drug LAU-7b in patients with COVID-19 disease, as part of a Phase 2 clinical trial.

Read more ...

Laurent Pharmaceuticals Receives a CAD 2.7M Financing from BioMed Propulsion Fund

MONTREAL, QC, Canada – December 4th, 2019

Laurent Pharmaceuticals Inc. (the “Company”), a biopharmaceutical company focusing on rare diseases, today announced that it has received the final approval for a CAD 2.7M loan from the Quebec Government through its BioMed Propulsion program. This financing will help support the Company’s Phase 2 clinical study evaluating LAU-7b in adult patients with cystic fibrosis (“CF”).

Read more ...


Laurent Pharmaceuticals to participate at NACFC 2019, in Nashville TN, October 31st - November 2nd 2019

Laurent Pharmaceuticals to participate at  BIO2019, in Philadelphia PA, June 3-6 2019